Among them, brentuximab vedotin (BV), an antibody-drug conjugate directed against the CD30 antigen, has shown encouraging results in patients with relapsed classical Hodgkin’s lymphoma (cHL) and relapsed anaplastic large cell lymphoma (ALCL) [17]. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.